Daiichi Sankyo Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for DAIICHI SANKYO INC, and when can generic versions of DAIICHI SANKYO INC drugs launch?
DAIICHI SANKYO INC has three approved drugs.
There are twenty-five US patents protecting DAIICHI SANKYO INC drugs.
There are three hundred and sixteen patent family members on DAIICHI SANKYO INC drugs in forty-five countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Daiichi Sankyo Inc
| International Patents: | 316 |
| US Patents: | 25 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
Drugs and US Patents for Daiichi Sankyo Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-001 | Jul 20, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 8,461,169 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Daiichi Sankyo Inc | TURALIO | pexidartinib hydrochloride | CAPSULE;ORAL | 211810-001 | Aug 2, 2019 | DISCN | Yes | No | 8,722,702 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Daiichi Sankyo Inc | VANFLYTA | quizartinib dihydrochloride | TABLET;ORAL | 216993-002 | Jul 20, 2023 | RX | Yes | Yes | 9,555,040 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 15 mg, 30 mg and 60 mg | ➤ Subscribe | 2019-01-28 |
International Patents for Daiichi Sankyo Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20140091619 | ⤷ Try a Trial |
| Israel | 200790 | ⤷ Try a Trial |
| Japan | 2014221765 | ⤷ Try a Trial |
| Denmark | 2201018 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Daiichi Sankyo Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1405852 | SPC/GB15/054 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN OR A SALT, SOLVATE OR N-OXIDE THEREOF; REGISTERED: UK EU/1/15/993/001-028 20150623 |
| 1405852 | CA 2015 00052 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN, HERUNDER EDOXABAN TOSILATE; REG. NO/DATE: EU/1/15/993/001-028 20150623 |
| 2140867 | PA2018005,C2140867 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619 |
| 1405852 | C01405852/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: EDOXABAN; REGISTRATION NO/DATE: SWISSMEDIC 65149 31.03.2015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
